Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Birabresib + GSK2801|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Birabresib||Y-803|MK-8628|OTX015|OTX-015||BET Inhibitor (Pan) 30||Birabresib (OTX015) is an inhibitor of the BET bromodomain proteins BRD3, BRD4, and BRD5, which inhibits interaction with acetylated histone H4, potentially resulting in decreased tumor cell proliferation (Mol Cancer Ther Nov 2013 12:C244, PMID: 29733771, PMID: 31204545).|
|GSK2801||GSK 2801|GSK-2801||GSK2801 is a bromodomain inhibitor that selectively inhibits BAZ2A/B and BRD9, which has potential antitumor activity (PMID: 31000582).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Birabresib + GSK2801||Preclinical - Cell culture||Actionable||In a preclinical study, Birabresib (OTX015) and GSK2801 treatment synergistically inhibited growth of a triple-negative breast cancer cell line in culture (PMID: 31000582).||31000582|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|